LUNG CANCER XENOGRAFT MODELS AVAILABLE

LUNG CANCER MODELS

Lung cancer is the leading cause of cancer related mortality in the United States.

There are two main histologic subtypes: non-small cell lung cancer (NSCLC) and small cell lung cancer(SCLC). NSCLC is further differentiated histologically into adeno-, squamous cell, and large cell carcinomas.

Small cell tumors metastasize very early but are relatively responsive to platinum based chemotherapy (DNA damaging drugs)

Patients with metastatic squamous cell carcinoma (SCC) have fewer treatment options than those with non-squamous NSCLC. There is a need for development of SCC models to facilitate the identification of molecular targets and development targeted therapies.

Request formal project quotation from Altogen Labs CRO.

MANY PDTX LUNG TUMOR MODELS ARE AVAILABLE:

Tumor type	Mutations	Comments
Squamous Cell Carcinoma	TP53, EGFR(R521K), PIK3CA	Sensitivity to antibody therapy (Cetuximab)
Adenocarcinoma	EGFR(L858R)	Increased sensitivity to TKIs¹
	EGFR(T790M), Exon 19 del²	Resistance to TKIs (erlotinib/gefitinib)
	KRAS(G12C), KRAS(G12A)	May decrease TKI sensitivity
	EML4-ALK translocation	Increased sensitivity to ALK/MET TKI crizotinib)
NSCLC³	TP53, KRAS(G12C)

¹TKI—Tyrosine Kinase Inhibitors: TKIs bind to and inhibit receptor Tyrosine kinases and suppress receptor mediated intracellular signaling. ²EGFR Exon 19 del: In-frame deletion of exon19 deleting a portion of the receptor Tyrosine kinase domain. ³NSCLC—Non-Small Cell Lung Carcinoma sensitivity to ionizing radiation.

Request lung cancer xenograft project quotation from Altogen Labs CRO.